To comprehensively review cardiorenal syndrome (CRS)-related research, this study analyzes its whole landscape and future trends from a bibliometric perspective. Using “cardiorenal syndrome” as the key word, a representative dataset of CRS was constructed in the Web of Science Core Collection (Science Citation Index Expanded) database up to November 2023. VOSviewer (version 1.6.18) and R-Studio (version 1.4) were used to visualize CRS-related author and national collaboration networks, hotspot distribution clustering and historical citation networks. The annual number of publications shows an upward trend, especially since 2009. The United States is the most active country and closely cooperates with European countries. Cardiorenal Medicine is the journal that publishes the most CRS-related research. Urology & Nephrology and Cardiovascular System & Cardiology are the most prominent areas of CRS literature output. The leaders in CRS-related research are Ronco C from Italy and Mccullough PA, from the United States. Combined with keyword co-occurrence, theme evolution, and strategic distribution analysis, it was found that centering on the mechanism of CRS (cardiovascular lesions, venous congestion, and fibrosis), prognosis (transplantation, dialysis, hospitalization, mortality) and cardiac function management (b-type natriuretic peptide, diastolic dysfunction, left ventricular hypertrophy) is a possible research direction for a long time to come. Although CRS has a relatively short history, it has received a lot of attention and is currently enjoying a high level of overall acceptance. In conclusion, this study explores the major research areas, frontiers and trends in CRS, which are important for future research.
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by diastolic dysfunction. Despite the increasing incidence of HFpEF, there is no available therapy that reduces the mortality rate of HFpEF. Zhigancao Tang has been used traditionally for the treatment of cardiovascular diseases in China. The use of traditional Chinese medicine (TCM) is associated with improvements in clinical syndromes and quality of life of patients. A randomized clinical trial should be conducted to provide clear evidence regarding the efficacy and safety of Zhigancao Tang granules for the treatment of HFpEF. A randomized, double-blinded, placebo-controlled clinical trial was proposed. A total of 122 patients with HFpEF will be randomly assigned to receive Zhigancao Tang granules or placebo for 12 weeks. The primary outcome measure is cardiac function. The secondary outcomes include measurement of the integral TCM syndrome score, echocardiography, 6-min walk test, N-terminal-pro hormone B-type natriuretic peptide level, atrial natriuretic peptide level, Minnesota Living with Heart Failure scale, and Lee’s scale. The outcome measures will be evaluated at baseline, 4 weeks, and 12 weeks. Adverse events will be evaluated from baseline till the 12-week follow-up period. The results of this trial will demonstrate whether Zhigancao Tang granules are effective and safe for treating HFpEF. ClinicalTrials.gov NCT04317339. Registered on 23 March 2020.
Acute arterial embolism due to tumor embolus is a rare complication in cancer patients, even rarer is lung tumor embolization leading to acute myocardial infarction. We report a patient who had a diagnosis of acute myocardial infarction(AMI)which was brought on by a coronary artery embolism by a metastatic lung cancer tumor. Clinicians need to be aware that tumor embolism can result in AMI. An 80-yeal-old male patient presented with persistent chest pain for 2 h and his electrocardiogram(ECG)showed anterior ST-segment elevation myocardial infarction. Instead of implanting a stent, thrombus aspiration was performed. Pathological examination of coronary artery thrombosis showed that a few sporadic atypical epithelial cells were scattered in the thrombus-like tissue. Combined with immune phenotype and clinical history, metastatic squamous cell carcinoma is more likely. We report a rare case of a patient who was diagnosed of AMI due to a coronary artery embolism by a metastatic mass from lung cancer. Since there is no evidence-based protocol available for the treatment of isolated coronary thrombosis, we used thrombus aspiration to treat thrombosis rather than implanting a stent.
Heart failure (HF) presents a significant global health challenge, caused by mitochondrial dysfunction, oxidative stress, and chronic inflammation, all of